Related Experiment Video
Updated: Jun 27, 2025
Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
Published on: May 4, 2018
Recent trends and challenges to overcome Pseudomonas aeruginosa infections
Alessandra Ammazzalorso1, Arianna Granese2, Barbara De Filippis1
1Department of Pharmacy, G. d'Annunzio University, Chieti, Italy.
Introduction:
Pseudomonas aeruginosa (PA) is a Gram-negative bacterium that can cause a wide range of severe infections in immunocompromised patients. The most difficult challenge is due to its ability to rapidly develop multi drug-resistance. New strategies are urgently required to improve the outcome of patients with PA infections. The present patent review highlights the new molecules acting on different targets involved in the antibiotic resistance.
Area Covered:
This review offers an insight into new potential PA treatment disclosed in patent literature. From a broad search of documents claiming new PA inhibitors, we selected and summarized molecules that showed in vitro and in vivo activity against PA spp. in the period 2020 and 2023. We collected the search results basing on the targets explored.
Expert Opinion:
This review examined the main patented compounds published in the last three years, with regard to the structural novelty and the identification of innovative targets. The main areas of antibiotic resistance have been explored. The compounds are structurally unrelated to earlier antibiotics, characterized by a medium-high molecular weight and the presence of heterocycle rings. Peptides and antibodies have also been reported as potential alternatives to chemical treatment, hereby expanding the therapeutic possibilities in this field.
Insights
New patented molecules show promise in combating multi-drug resistant Pseudomonas aeruginosa (PA) infections. These novel compounds, including peptides and antibodies, target innovative pathways to overcome antibiotic resistance in PA.
Area of Science:
- Bacteriology
- Pharmacology
- Patent Law
Background:
- Pseudomonas aeruginosa (PA) is a Gram-negative bacterium causing severe infections, particularly in immunocompromised individuals.
- A major challenge in treating PA infections is its rapid development of multi-drug resistance.
- Novel therapeutic strategies are urgently needed to improve patient outcomes.
Purpose of the Study:
- To review and summarize recent patent literature (2020-2023) on new molecules targeting antibiotic resistance in Pseudomonas aeruginosa.
- To identify innovative therapeutic targets and structurally novel compounds for PA treatment.
Main Methods:
- Conducted a broad search of patent documents claiming new PA inhibitors.
- Selected and summarized molecules with reported in vitro and in vivo activity against PA species.
- Categorized findings based on the explored antibiotic resistance targets.
Main Results:
- Identified structurally novel compounds, distinct from existing antibiotics, with medium-high molecular weight and heterocycle rings.
- Highlighted peptides and antibodies as emerging alternative therapeutic options.
- Explored various innovative targets involved in PA antibiotic resistance.
Conclusions:
- Recent patent literature reveals promising new chemical entities and biologics for combating multi-drug resistant PA.
- These novel approaches offer expanded therapeutic possibilities beyond traditional antibiotics.
- Continued research and development in this area are crucial for addressing the growing threat of PA infections.
More Related Videos
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia III: Complications and Assessment
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...